Investment Analysts’ Weekly Ratings Changes for Artivion (AORT)

Artivion (NYSE: AORT) recently received a number of ratings updates from brokerages and research firms:

• 4/25/2026 – Artivion was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/20/2026 – Artivion had its “buy” rating reaffirmed by Needham & Company LLC.
• 4/11/2026 – Artivion was upgraded by Wall Street Zen from “hold” to “buy”.
• 4/10/2026 – Artivion was upgraded by LADENBURG THALM/SH SH from “neutral” to “buy”. They now have a $42.00 price target on the stock.
• 4/7/2026 – Artivion had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $58.00 price target on the stock.
• 3/5/2026 – Artivion was given a new $55.00 price target by Stifel Nicolaus.

Insider Buying and Selling at Artivion

In related news, CAO Amy Horton sold 901 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $34,039.78. Following the completion of the transaction, the chief accounting officer owned 139,088 shares of the company’s stock, valued at $5,254,744.64. This represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Marshall S. Stanton sold 2,149 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $81,189.22. Following the transaction, the senior vice president owned 60,097 shares of the company’s stock, valued at approximately $2,270,464.66. This represents a 3.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 133,043 shares of company stock worth $4,977,158 in the last 90 days. 6.30% of the stock is currently owned by insiders.

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.